Clinical Trial Update: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Budesonide/Albuterol MDI (PT027) in adults and children aged 4+ with asthma has completed and results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Budesonide/Albuterol Metered-dose Inhaler (PT027) (budesonide-albuterol)

Snippet

Sponsor: Bond Avillion 2 Development LP | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2022-09-28